Nicholas G. Beacher and Martin J. Brodie contributed equally to this work.
MB is on the advisory boards of the following pharmaceutical companies:
Eisai, UCB Pharma, GlaxoSmithKline, Lundbeck, Takeda, GW Pharmaceuticals and Bial. NB and CG have no competing interests to declare.
NB performed the assessment of the patient, reviewed the available literature and drafted the manuscript. CG performed assessment of the patient and drafted the manuscript. MB reviewed the medical literature and drafted the manuscript. All authors read and approved the final manuscript.
1. Nicholas G. Beacher. BDS, MFDS (RCPSG). Clinical Lecturer and Honorary StR in Special Care Dentistry.
2. Martin J. Brodie MBChB, MRCP, MD, FRCP. Professor of Medicine and Clinical Pharmacology and Director of Epilepsy Unit Glasgow Western Infirmary, Epilepsy Unit, Western Infirmary, Glasgow, UK.
3. Christine Goodall BSc(Hons), BDS(Hons), FHEA, FDS(OS), Hon MFPH, PhD. Senior Clinical Lecturer and Consultant in Oral Surgery and Sedation.
Dyspigmentation of the oral mucosa has a multitude of aetiological causes. Retigabine, a new antiepileptic drug, has the potential side effect of inducing a blue/purple pigmentation of the oral mucosa in addition to the skin, lips, nails and retina of the eyes. This article presents a unique case of dyspigmentation present in the oral mucosa of the hard palate which has previously been unreported in the dental literature.
A 70 year old white male presented to a secondary care oral surgery department with an unusual asymptomatic pigmented lesion present in the hard palate of the oral cavity. The pigmentation was remarkable for its distinct blue/purple colouration which was associated with a similar discolouration of the nail beds of the hands. This is believed to be a side effect of the anti-epileptic medication retigabine.
The dental profession and wider healthcare community should be made fully aware of the potential side effect of oral dyspigmentation associated with the novel anti-epileptic medication retigabine. Enhanced knowledge of the causative role of retigabine in dyspigementation of the oral mucosa will allow the practitioner to make an appropriate diagnosis. As far the authors are aware this is reaction is unreported in the dental literature and should be disseminated to the wider oral health professional’s community.
European Medicines Agency. 2011. CHMP Assessment Report; retigabine. Procedure No.EMEA/H/C/001245. EMA London. 20 January 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/001245/WC500104839.pdf
F.D.A.2013. FDA Drug Safety Communication: FDA approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration. FDA, Maryland. 26 April 2013. http://www.fda.gov/Drugs/DrugSafety/ucm372774.htm
Shkolnik TG, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150(9):984–9. CrossRef
Huber B, Bocchicchio M. A retrospective evaluation of retigabine in patients with high therapy-resistant epilepsy. Epilepsy and Behavior, in press.
Alawi F. Lesions of the oral cavity: an update. Dent Clin North America. 2013;57(4):699–710. CrossRef
Akintoye SO, Boyce AM, Collins MT. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(3):10.1016. CrossRef
European Medicines Agency. 2013. European Medicines Agency recommends restricting Trobalt to last-line therapy in partial epilepsy Procedure No.EMEA/H/C/001245. EMA, London. 20 January 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/human/001245/WC500143799.pdf
Prescott J, Evans C, Saenz AA. 2014. Pigmentary abnormalities (discolouration) associated with exogabine/retigabine treatment: non clinical aspects. Presented at American Epilepsy Society, Seattle, Washington, USA, 5-9 th December.
- A case report: retigabine induced oral mucosal dyspigmentation of the hard palate
Nicholas G. Beacher
Martin J. Brodie
- BioMed Central
Neu im Fachgebiet Zahnmedizin
Mail Icon II